| 📌 The essentials A study published in Menopause, the journal of The Menopause Society, analyzed data from more than 255,000 patients and found that only 36% of women diagnosed with premature ovarian insufficiency (POI) received hormone therapy, despite consistent international guidelines recommending it. The study was conducted in tertiary hospitals in Saudi Arabia, providing real-world prescribing data from a region where HT underuse is documented but less studied. The gap matters because women with POI who do not receive hormone therapy until the average age of natural menopause face substantially higher risks of osteoporosis, cardiovascular disease, cognitive decline, and mood disorders compared with women who reach menopause naturally after age 40. The finding is consistent with what the NIH and multiple research groups have documented in U.S. and European populations: HT underuse in POI is a global problem, not a regional one. |
|---|
Premature ovarian insufficiency is not the same as early menopause, though the terms are often used interchangeably. It is a clinical diagnosis made when a woman loses normal ovarian function before the age of 40, with ovarian function sometimes fluctuating rather than ceasing entirely. About 1 in 100 women is affected. Many are in their 20s and 30s. Some are teenagers. Most receive a diagnosis only after months or years of being told their irregular periods are stress, overexercise, or a thyroid issue.
When the diagnosis finally arrives, it carries consequences that extend well beyond infertility, which tends to dominate the conversation. Women with POI face the same estrogen deficiency that women in natural menopause experience, but they face it decades earlier, and they face it for far longer. The cumulative health burden of that estrogen deficit over 10 to 20 additional years is substantial, and it is largely preventable with hormone therapy.
A new study published in Menopause in January 2026 quantifies how large the treatment gap actually is. Only 36% of women diagnosed with POI received hormone therapy. That means roughly two out of three women with a condition that consistently generates international guideline recommendations for HT are not getting it.
What POI Is and Why It Is Different from Natural Menopause
Premature ovarian insufficiency is defined by two criteria: age younger than 40, and biochemical confirmation of ovarian dysfunction, typically elevated follicle-stimulating hormone (FSH) levels on two measurements taken at least four weeks apart. The ovaries have not failed completely in most cases. Intermittent ovarian activity and even spontaneous pregnancy can occur in 5 to 10% of women after diagnosis. But sustained, predictable hormone production has been disrupted.
The distinction from natural menopause matters for treatment and prognosis. In natural menopause, the gradual decline in estrogen production reflects a process that unfolds over the expected lifespan, and cardiovascular, bone, and neurological systems have had decades to adapt. In POI, the estrogen deficit arrives abruptly and at an age when those systems have not yet had that adaptation. The resulting long-term risks are not equivalent.
| The long-term health consequences of untreated POI Bone: Osteoporosis risk is substantially elevated in women with POI, driven by the loss of estrogen’s protective effect on bone mineral density. Women with POI have significantly lower bone density than age-matched peers, and the risk of fragility fractures accumulates with each decade of untreated estrogen deficiency. Even in the study reviewed here, which found that 6.8% of participants had a documented diagnosis of osteopenia and 4.9% had osteoporosis, hormone therapy uptake in those women remained low. Cardiovascular: Estrogen has cardioprotective effects, and its premature loss is associated with higher rates of cardiovascular disease, hypertension, and adverse lipid profiles in women with POI compared with age-matched controls. Women with POI who do not receive HT have been shown to have cardiovascular risk profiles closer to those of age-matched men than to age-matched women who entered menopause at the expected time. Cognitive and neurological: There is growing evidence that estrogen plays a role in brain health and cognitive function, and some studies suggest increased risk of cognitive decline and dementia in women with untreated POI. The mechanism is not fully established, but the long window of estrogen deficiency is a plausible contributor. Mood and mental health: Depression, anxiety, and sexual dysfunction occur at higher rates in women with POI than in age-matched controls. Estrogen has direct effects on neurotransmitter systems involved in mood regulation, and the psychological burden of the diagnosis itself, including grief over fertility loss and uncertainty about long-term health, compounds the biological effects. |
|---|
What the Study Found
The study, published in the January 2026 issue of Menopause, was conducted across tertiary hospitals in Saudi Arabia. Researchers analyzed data from more than 255,000 patients with the objective of determining how often hormone therapy is prescribed for women with POI and what factors are associated with receiving it.
Key findings:
The prevalence of POI among women who underwent FSH testing was 5.05%. This is higher than the 3.5% global estimate from prior systematic reviews, though the difference likely reflects selection bias: women being tested for FSH in tertiary settings are more likely to have symptoms suggestive of ovarian dysfunction than the general population.
Of women diagnosed with POI, only 36% received hormone therapy. That is the central number, and it is consistent with underuse estimates from other regions. A previous systematic review found that across multiple countries, hormone therapy initiation rates in women with POI range from approximately 35 to 50%, with wide variation based on geography, healthcare system, and provider specialty.
Amenorrhea (absence of menstrual periods) was the most common presenting symptom, affecting 42.4% of participants. This is clinically important context: amenorrhea is the symptom most likely to prompt FSH testing and subsequent POI diagnosis, but it is also a symptom that can persist for years without triggering a formal workup in healthcare systems where irregular periods are routinely attributed to stress, thyroid dysfunction, or other causes.
Hormone therapy uptake remained low even in the subset of women who already had a documented diagnosis of bone density loss: 6.8% with osteopenia and 4.9% with osteoporosis were identified in the cohort, and HT use remained below expected rates in these groups. This finding is particularly striking because bone protection is one of the most clearly established benefits of HT in POI and one where the risk-benefit calculation most clearly favors treatment.
Geographic context: This study was conducted in Saudi Arabia, and regional differences in hormone therapy use are well established and real. Cultural, religious, and healthcare system factors influence prescribing patterns in ways that limit direct extrapolation. However, the authors note that the NIH and multiple U.S.-based research groups have documented comparably low HT utilization in American women with POI, and the ESHRE POI guideline explicitly addresses the underuse problem as a global phenomenon.
The WHI Shadow: Why Fear of Hormone Therapy Has Outlasted the Evidence That Created It
To understand why two-thirds of women with POI are not receiving a treatment that guidelines consistently recommend, you need to understand what happened in 2002.
The Women’s Health Initiative (WHI) was a large, landmark study of hormone therapy in postmenopausal women. In 2002, the combined estrogen-progestin arm of the trial was stopped early after researchers found increased risks of breast cancer, heart disease, stroke, and blood clots. The results generated enormous media coverage and fundamentally shifted prescribing behavior. HT use in menopausal women plummeted within months and has never fully recovered.
The problem is that the WHI findings were widely misapplied. The study enrolled women with an average age of 63, the majority of whom were more than 10 years past menopause. The findings were about hormone therapy initiated years after menopause in women for whom estrogen replacement was not restoring a physiological state but adding hormones to a body that had long since adapted to their absence. The results do not apply to women in their 20s and 30s with POI, in whom HT is restoring estrogen levels to what would naturally be present at their age.
Major medical organizations have tried to correct this misapplication. The Menopause Society’s 2023 position statement explicitly states that for women younger than 40 with POI, HT is recommended until the average age of natural menopause (approximately 51) in the absence of contraindications, and that the risks identified in the WHI do not apply to this population. The ESHRE POI guideline, the NICE guideline on menopause, and the Royal Australian and New Zealand College of Obstetricians and Gynaecologists all say the same thing.
The message has not reached clinical practice consistently, and it has reached patients even less.
What the Guidelines Actually Say
International clinical guidelines on POI are consistent in their core recommendation: hormone therapy should be offered to women with POI until approximately the average age of natural menopause, roughly 51 years in most populations, unless there is a specific contraindication.
The rationale is straightforward. HT in POI is not pharmacological intervention in the way that HT in a 60-year-old is. It is replacement of hormones that the body would naturally be producing at that age but is not. The risks associated with HT in older postmenopausal women do not apply because the frame of reference is different: POI in a 28-year-old is not the same biological situation as menopause in a 63-year-old.
The specific formulation of HT in POI is also distinct from what is typically used in natural menopause. Estrogen doses needed to restore physiological levels in women with POI are generally higher than standard low-dose HT formulations used in natural menopause. Many standard preparations are designed for symptom management in older postmenopausal women at the lowest effective dose. Women with POI need estrogen levels comparable to what their peers have naturally, which may require different dosing strategies and routes of administration.
Women with an intact uterus also need progestogen to protect the uterine lining from unopposed estrogen stimulation. The choice of progestogen formulation matters: micronized progesterone (body-identical progesterone) appears to carry a lower breast cancer risk signal than synthetic progestins based on current evidence, though the absolute risk differences in young women are small.
Barriers to Treatment: What the Research Points To
The study’s authors identify two primary drivers of HT underuse in POI: provider knowledge gaps and patient fears. The research literature supports both.
Provider factors: Many women with POI are seen by general practitioners or gynecologists without subspecialty training in reproductive endocrinology or menopause medicine. Studies in multiple countries have found that a substantial proportion of providers are unfamiliar with current POI guidelines, underestimate the long-term health risks of untreated POI, or have not updated their prescribing practices since the 2002 WHI publication. Diagnosis itself is often delayed: the average time from first symptom to POI diagnosis has been estimated at 4 to 6 years in some studies, reflecting both the intermittent nature of ovarian function in some cases and the tendency to attribute symptoms to other causes.
Patient factors: Fear of breast cancer is the dominant barrier on the patient side, a direct legacy of the 2002 WHI coverage. Women who decline HT for POI often cite cancer risk as their primary concern, even though the evidence does not support elevated breast cancer risk from physiological estrogen replacement in a young woman with POI. Addressing this misunderstanding requires time, clear communication, and a provider who is confident explaining why the WHI findings do not apply to a 32-year-old whose ovaries stopped working.
Fertility concerns can also complicate the HT conversation in a counterproductive way. Some women with POI delay hormone therapy out of concern that it will reduce their already limited chances of spontaneous pregnancy. Current evidence does not support this concern: HT does not suppress the intermittent ovarian activity that underlies spontaneous ovulation in POI, and the cardiovascular and bone protection benefits of starting HT early outweigh theoretical fertility concerns in most cases.
What Women with POI Should Know
If you have been diagnosed with POI, or are being evaluated for it, here is what the current evidence supports:
Hormone therapy is recommended. Every major international guideline recommends HT for women with POI until approximately age 51, unless a specific contraindication exists such as a personal history of hormone-receptor-positive breast cancer or a known high-risk thrombophilia.
The WHI does not apply to you. The risks identified in that study are not relevant to estrogen replacement in women whose ovaries stopped functioning before age 40. This is worth discussing explicitly with your provider if concern about those findings is part of the conversation.
The dose may need to be higher than standard HT. Low-dose preparations designed for older postmenopausal women may not restore your estrogen to physiological levels. Ask your provider whether the formulation and dose is appropriate for your age rather than simply the lowest available option.
Delaying treatment has real consequences. Every year without HT in POI is a year of accelerated bone loss, cardiovascular risk accumulation, and potential neurological effects. The benefits of starting HT early and continuing it to the average age of natural menopause are well established in the guideline literature.
Seek a provider with POI or reproductive endocrinology experience. Not all gynecologists have current, guideline-concordant knowledge about POI management. The Menopause Society’s practitioner finder can help identify providers with menopause medicine certification. If you are also navigating fertility questions, a reproductive endocrinologist is the appropriate specialist.
For related women’s health coverage on Health Evidence Digest, see our posts on GLP-1 medications and PCOS fertility research in 2026, new 2026 cervical cancer screening guidelines including self-collection, and the first non-hormonal endometriosis drug entering clinical trials.
Sources
The Menopause Society press release: Hormone Therapy Underused in Women With Premature Ovarian Insufficiency. menopause.org. January 21, 2026.
ESHRE POI Guideline: Management of women with premature ovarian insufficiency. European Society of Human Reproduction and Embryology. 2024.
Menopause Society position statement: The 2023 Menopause Society Position Statement on Hormone Therapy. menopause.org.
NICE guideline on menopause: Menopause: diagnosis and management. NICE guideline NG23. nice.org.uk.
POI systematic review and long-term outcomes: Golezar S, et al. The global prevalence of primary ovarian insufficiency and early menopause: a meta-analysis. Climacteric. 2019.
POI clinical review: Webber L, et al. POI: pathophysiology, presentation, diagnosis, and management. BMJ. 2016.
Cognitive effects of early menopause: Phung TK, et al. Dementia risk in women with premature ovarian insufficiency and early menopause. PMC9585583.
WHI overview: Women’s Health Initiative. National Heart, Lung, and Blood Institute.
NICHD POI resource: Premature Ovarian Insufficiency. nichd.nih.gov.
Menopause Society practitioner finder: Find a Menopause Healthcare Practitioner. menopause.org.
| Disclaimer: Health Evidence Digest provides general information about health research for educational purposes. This content is not a substitute for professional medical advice, diagnosis, or treatment. Decisions about hormone therapy for premature ovarian insufficiency should be made in consultation with a qualified healthcare provider who can evaluate individual health history, contraindications, and treatment goals. |
|---|
Leave a Reply